How nearly dying helped me discover my own cure (and many more) | David Fajgenbaum

Episode Summary

Executive Summary: David Fagenbaum recounts surviving Castleman disease by repurposing existing drugs, then launching EveryCure to use AI to find hidden uses for already-approved medicines. The talk argues that many diseases lack treatments not because cures don’t exist, but because incentives and discovery systems fail to find them—especially for rare diseases and generic drugs.

Main Topics: Personal survival through drug repurposing (Priority: 5/5): Fagenbaum describes his near-death experience with Castleman disease, repeated relapses, and how an off-label transplant drug put him into long-term remission. The case for repurposing existing medicines (Priority: 5/5): He explains that drugs can be effective for multiple diseases when underlying biology overlaps, citing examples like Viagra and thalidomide, and noting that off-label prescribing is common. AI as a discovery engine for hidden cures (Priority: 5/5): EveryCure uses artificial intelligence to match approved drugs with diseases at scale, prioritizing promising drug-disease pairs faster than human teams can. Structural barriers and misaligned incentives (Priority: 4/5): Fagenbaum argues repurposing is neglected because it is not profitable, especially for rare diseases and generic drugs, and no major institution has taken responsibility for systematic discovery. Early impact of EveryCure (Priority: 4/5): The organization has already advanced multiple repurposed treatments and helped patients through both newly discovered matches and underused existing ones. Call for public participation and funding (Priority: 3/5): He asks listeners to share repurposing stories, amplify treatments, and donate so EveryCure can expand trials and accelerate access.

Key Arguments: Many life-saving treatments already exist in pharmacies but remain undiscovered for specific diseases. Repurposing can be dramatically faster and cheaper than developing new drugs from scratch. Off-label prescribing shows that approved drugs can legally be used beyond their original indications when benefits outweigh risks. AI can analyze the full landscape of drugs and diseases to identify hidden matches at a scale humans cannot match. The main obstacle is not scientific possibility but economics: generic drugs and rare diseases do not attract enough profit to fund trials. Systematic repurposing could help millions of patients with rare diseases and conditions with limited options.

Data Points: Years in remission: Over 11 years - Fagenbaum says the repurposed drug he tested on himself has kept him in remission for more than a decade. Relapses before remission: 5 times in 3 years - He nearly died repeatedly before finding the treatment that worked. Age at first near-fatal illness: 25 years old - He was a medical student and former college quarterback when Castleman disease nearly killed him. FDA-approved drugs: About 4,000 - He contrasts the number of approved drugs with the much larger number of diseases. Diseases without approved therapy: Over 14,000 - He argues that many diseases still have no approved treatment. Prescriptions that are off-label: 1 in 4 - He cites the prevalence of off-label prescribing in the U.S. Cost of new drug development vs repurposing: Less than 1% - He says repurposing can be far cheaper than developing new drugs. AI coverage: 4,000 drugs and 18,000 diseases - EveryCure scans the universe of approved drugs and diseases to find matches. Repurposed treatments advanced by EveryCure: 14 - He says the nonprofit has already moved multiple treatments forward for different diseases. Target by 2030: 15 to 25 treatments - EveryCure aims to repurpose this many treatments through its AI-powered engine by 2030. Generic drugs among approved medicines: 80% - He notes that most approved drugs are generic, reducing commercial incentive to study new uses.

Pivotal Quotes: "Hope alone is not enough." — David Fagenbaum: He explains the moment he realized he needed to actively search for a treatment to survive. "What if we haven't tried everything? What if there's a solution out there for them and thousands, maybe even millions more with their disease?" — David Fagenbaum: He frames the moral urgency of systematically finding hidden uses for existing drugs. "we have something." — David Fagenbaum: His concluding vision is to replace 'we've tried everything' with a message of real therapeutic options.

Implications: Drug repurposing could rapidly expand treatment access for rare and neglected diseases at low cost. If AI-driven discovery scales, patients may benefit from existing medicines years sooner than through conventional drug development.